Research suggests vapers are vulnerable to pneumonia
(European Lung Foundation) The vapor from e-cigarettes seems to help pneumonia-causing bacteria stick to the cells that line the airways, according to research published in the European Respiratory Journal.
Authors: Nishino T PMID: 29780144 [PubMed - as supplied by publisher]
Authors: Asato Y, Kamitani T, Ootsuka K, Kuramochi M, Nakanishi K, Shimada T, Takahashi T, Misu T, Aoki M, Fujihara K, Kawabata Y Abstract We herein report the case of a 76-year old man with aquaporin-4-Immunoglobulin-G (AQP4-IgG)-positive neuromyelitis optica spectrum disorder (NMOSD), in whom transient interstitial pulmonary lesions developed at the early stage of the disease. Chest X-ray showed multiple infiltrative shadows in both upper lung fields, and computed tomography revealed abnormal shadows distributed randomly in the lungs. Surgical lung biopsy showed features of unclassifiable interstitial pneumonia, ...
Conclusion Serotype data from this study helped in accurate estimation of PCV-13 and PPV-23 protective coverage against serotypes causing IPD in India as 58.7% (95% CI: 53.8, 63.4) and 67.4% (95% CI: 62.7, 71.8) respectively. Penicillin non-susceptibility in meningeal IPD cases is 27.4%. Empirical therapy for meningeal IPD must be cephalosporin in combination with vancomycin since cefotaxime non-susceptibility in meningeal IPD is 9.9%.
We present an autopsy report of Achromobacter endocarditis involving the native valves in a woman with end-stage renal disease (ESRD) on hemodialysis (HD).
Despite advances in treatment and prevention, the pneumococcus continues to be a dominant cause of severe pneumonia and sepsis and of otitis media, sinusitis, and nonbacteremic pneumonia. Lewnard and colleagues (Infect Immun 86:e00727-17, 2018, https://doi.org/10.1128/IAI.00727-17) used a unique data set of nasopharyngeal and middle ear fluid samples to provide further insight into the progression of nasopharyngeal pneumococcal colonization to disease. They report the comparative rate of progression from colonization to otitis media by serotype, providing insight into how conjugate vaccines that do not reduce the overall p...
Nabriva Therapeutics announced positive results Monday from its second large-scale, late-stage clinical trial of its experimental therapy for community-acquired bacterial pneumonia (CABP). The biopharmaceutical company, which has operations in Dublin, Ireland and King of Prussia, plans to file a new drug application for the therapy – called Lefamulin – with the Food and Drug Administration during the fourth quarter of this year. Nabriva’s stock surged by more than 20 percent in pre-market…
(Reuters) - Nabriva Therapeutics Plc's antibiotic drug to treat a common form of pneumonia met the main goal of a key clinical trial, but concerns over its side effects sent the drug developer's shares down 13 percent on Monday.
Condition: Pneumonia, Mycoplasma Interventions: Drug: Doxycycline; Drug: Azithromycin Sponsor: National Taiwan University Hospital Recruiting
(Reuters) - Nabriva Therapeutics Plc said on Monday its antibiotic to treat adults with a common form of pneumonia met the main goal of a second late-stage study, putting the company on track to file for the drug's approval in the fourth quarter of 2018.